# Thymulin Dosage in Studies: Research Doses, Routes, and Half-Life > Thymulin dosage exists only as study findings - nanogram-to-microgram doses in animals, several research routes, and an uncharacterized human half-life. No human protocol. The doses, routes, and pharmacokinetics on record - all of them study parameters in animals and cells, none of them a human protocol. ## The short version, in plain words There is no established thymulin dosage for people - so this page reports only what researchers gave to animals and cells. In rodent studies the amounts were tiny: nanograms to a few micrograms per animal, given by injection into the belly cavity or the brain fluid, or as roughly 100 nanograms per kilogram a day under the skin in one rat study. The gene-therapy work doesn't dose the peptide at all - it delivers a single shot of the gene instead. None of these numbers is a recommendation, a regimen, or a protocol a person should follow. They are study settings, written down so the record is complete. ## Thymulin Peptide Dosage in Animal and In-Vitro Studies Thymulin peptide dosage in the published record lives entirely in animal and in-vitro work. Reported research doses include 0.1-1 microg intracerebroventricularly (into the brain's fluid spaces) and 1-1000 ng intraperitoneally (into the abdominal cavity) in rodent pain models, and roughly 100 ng/kg/day subcutaneously in a rat pulmonary-hypertension study [4]. In one mouse tissue-protection study, serum thymic factor was given at 50 microg per animal before an LPS challenge [15]. Anti-inflammatory mouse work dosed thymulin daily for two weeks before the challenge, with the numeric amount reported in the source rather than the abstract [6]. These are study parameters tied to a species, a route, and an endpoint - not a scale that converts to a human dose. The atlas reports them so the literature is legible, never as guidance. ## What is the dosage of thymulin peptide? There is no established human dose. Studies report research doses in animals - for example 0.1-1 microg intracerebroventricularly, 1-1000 ng intraperitoneally, or about 100 ng/kg/day subcutaneously - and these are study parameters, not protocols for people [4]. Gene-therapy work used a single vector dose rather than a peptide dose [5]. No human thymulin dosing regimen is established in the literature. ## What doses of thymulin were used in animal studies? Reported research doses include 0.1-1 microg intracerebroventricularly and 1-1000 ng intraperitoneally in rodent pain models, and roughly 100 ng/kg/day subcutaneously in a rat pulmonary-hypertension study [4]; a separate mouse study used 50 microg per animal of serum thymic factor before LPS [15]. Gene-therapy work used a single adenoviral or nanoparticle vector dose rather than a peptide dose [5][7]. ## How is thymulin administered in research? In animal and in-vitro studies, thymulin has been given by intraperitoneal, subcutaneous, and intracerebroventricular routes, with intratracheal and intramuscular delivery used for gene-therapy vectors and a topical zinc-thymulin formulation used in a small human cosmetic pilot [5][7]. The route follows the question: systemic for inflammation, central for CNS and pain work, airway for the inhaled gene therapy [6][7]. ## Is thymulin taken as an injection? In research, thymulin has been delivered by injection routes - intraperitoneal, subcutaneous, and intracerebroventricular - in animals, and a human topical zinc-thymulin pilot used a skin formulation [7]. There is no approved human injectable thymulin product. Any injection described in the literature is an experimental route in a study animal, not a human regimen. ## What is the half-life of thymulin? As a small peptide, native thymulin has a short circulating half-life, but a precise human pharmacokinetic half-life is not well established in the public literature [5]. That short native persistence is one reason gene-therapy approaches were developed - to sustain circulating thymulin from an internal source rather than chase it with repeated dosing [5][7]. The honest statement is that the thymulin half-life in humans is uncharacterized. ## What is known about thymulin safety and side effects? Honestly, little in humans. Thymulin is a research peptide, not an FDA-approved drug and not a dietary supplement, and the human safety record is sparse and dated - several human studies used a synthetic analog (nonathymulin) rather than native thymulin [5]. The preclinical work reports therapeutic and protective effects in animal models rather than systematic toxicology [6][7]. Because activity is strictly zinc-dependent, reported effects are also entangled with zinc status, which complicates any clean safety read. There is no established human side-effect profile, and nothing here is dosing guidance. --- A deep-water field atlas of the thymulin literature - the zinc-bound thymic peptide catalogued like a vanishing species, the established findings pressed beside the human-data gaps and the molecule kept distinct from thymosin alpha-1 and thymalin; no clinic behind the specimen sheet and nothing here dosed, prescribed, or sold.